KB
REGN icon

Kimelman & Baird’s Regeneron Pharmaceuticals REGN Stock Holding History

Kimelman & Baird’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.39M Buy
10,856
+10,542
+3,357% +$8.07M 0.69% 34
2025
Q4 		$242K Buy
314
+260
+481% +$177K 0.02% 109
2025
Q3 		$30.4K Hold
54
– – ﹤0.01% 216
2025
Q2 		$28.4K Hold
54
– – ﹤0.01% 224
2025
Q1 		$34.2K Hold
54
– – ﹤0.01% 217
2024
Q4 		$38.5K Hold
54
– – ﹤0.01% 210
2024
Q3 		$56.8K Hold
54
– – ﹤0.01% 178
2024
Q2 		$56.8K Buy
+54
New +$52.3K ﹤0.01% 176
2017
Q1 		– Sell
-550
Closed -$202K – 124
2016
Q4 		$202K Buy
+550
New +$209K 0.03% 113

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Kimelman & Baird's REGN Position: Q1 2026 in Review

Kimelman & Baird increased its Regeneron Pharmaceuticals (REGN) stake by 3,357% in Q1 2026, buying an estimated $8.07M and bringing the position to 10,856 shares worth $8.39M. The position accounts for 0.69% of the portfolio, ranked #34.

Kimelman & Baird first reported a position in REGN in Q4 2016 and has held it in 9 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Kimelman & Baird held 10,856 shares of Regeneron Pharmaceuticals worth $8.39M as of Q1 2026.
  • Kimelman & Baird bought 10,542 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $8.07M.
  • Regeneron Pharmaceuticals made up 0.69% of Kimelman & Baird's portfolio in Q1 2026, its #34 holding.
  • Kimelman & Baird first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 9 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Kimelman & Baird's 13F filing for Q1 2026, filed 13 May 2026.